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      Human endogenous retroviruses (HERVs) are remnants from ancient retroviral 
infections, and most of them are inactive in normal tissues. One family of HERV, 
HERV-K, is found to be associated with multiple human cancers including breast 
cancer, pancreatic cancer and melanoma, but the causal relationship between HERV-K 
and cancer is still unclear. Increased expression of HERV-K in melanoma cells 
correlates with malignant transformation, while a serological response to HERV-K in 
breast cancer or melanoma patients correlates with survival probability. However, the 
mechanism behind these observations remains obscure. Our laboratory reported that 
anti-HERV-K envelope (Env) protein antibodies show antitumor potential in targeting 
breast tumors, indicating that HERV-K Env (Kenv) may play an important role in 
tumorigenesis. In this study, we used either knockdown (main focus) or over-expression 
approach, to investigate the role of Kenv in breast cancer, pancreatic cancer, and 
melanoma. Compared to the control cells, all the cancer cell lines transduced with Kenv-
specific shRNA (shRNAenv)  exhibited lower proliferation rates and lower tumorigenic 
potential in vitro, and some showed lower migration/ invasion rate.  In vivo, tumorigenic 
potential of all the shRNAenv transduced cell lines was found to be reduced after 
inoculation into nude mice or NOD/SCID gamma (NSG) mice. Moreover, results from 
RNA Seq and Ingenuity Pathway Analysis (IPA) suggested the involvement of Kenv in 
vi 
 
the mevalonate pathway.  In addition, introduction of Kenv into the premalignant human 
breast cell line MCF-10AT led to increased cell proliferation and colony formation. 
These results suggest that Kenv plays specific and important roles in progression of  
human breast cancer, pancreatic cancer, and melanoma. 
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Chapter 1 Introduction 
      In 1908, Oluf Bang and Vilhelm Ellerman studied leukemia in chickens and found 
that the disease could be transmitted to new chickens by cell-free tissue filtrates. In 1910-
1911, Peyton Rous confirmed similar results for solid tumors in chickens and 
subsequently isolated the infectious agent, a virus later named as Rous sarcoma virus 
(RSV) (1). Based on these findings, a theory that viruses can cause cancer was proposed. 
Since then, more and more evidence has been accrued to support this theory: in 1933, 
Richard Edwin Shope discovered the first mammalian tumor virus, Shope 
papillomavirus, in rabbit (2); in 1964, Anthony Epstein, Bert Achong and Yvonne Barr 
discovered the first human cancer virus, Epstein-Barr Virus (EBV), from Burkitt 
lymphoma cells (3); in 1970, G. Steven Martin discovered the first confirmed oncogene, 
v-src (which was termed a few years later), from a mutant RSV strain (4). Until the 
present, 6 viruses acknowledged to cause human cancer have been discovered: EBV 
(Burkitt’s lymphoma, Hodgkin’s lymphoma, nasopharangeal carcinoma), hepatitis B 
virus (HBV) and hepatitis C virus (HCV) (hepatocellular carcinoma), human T-
lymphotropic virus 1 (HTLV-1) (adult T-cell leukemia and lymphoma), high risk human 
papillomavirus (HPV) (cervical cancer), and Kaposi’s sarcoma-associated herpesvirus 
(KSHV or HHV8) ( Kaposi’s sarcoma) (5-8). 
         Despite only 6 human cancer viruses having been widely acknowledged, more 
viruses have been proven to be at least associated with human cancers, such as Merkel 
cell polyomavirus (MCPyV) (Merkel cell carcinoma), cytomegalovirus (CMV) (brain 
tumor) (6), and human endogenous retrovirus-K (HERV-K) (seminoma, breast cancer, 
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prostate cancer, ovarian cancer, melanoma) (9). This section will focus on general 
features of HERV-K and its association with multiple human cancers. 
1.1 Human endogenous retrovirus (HERV) 
1.1.1 HERV features 
      Retroviruses are RNA viruses defined by their expression of reverse transcriptase 
(RT). During the replication cycle of retroviruses (Figure 1), there are two critical steps 
which are intermediated by two virally coded enzymes:  reverse transcription, the 
conversion of viral genomic RNA into DNA, mediated by RT; and the integration of 
newly-synthesized viral DNA into the host genome that follows reverse transcription, 
mediated by integrase (10). Virion particles are spherical with a diameter of 
approximately 80-100 nm. Virus particles contain 2 copies of sense RNA of ~8 to 10 kb 
in length, which together with nucleocapsid protein form the viral ribonucleoprotein 
complex. The nucleocapsid is surrounded by a spherical layer of protein, called the 
capsid protein, and the outer layer is the viral envelope, which is a lipid bilayer 
membrane distributed with envelope glycoprotein. The schematic structure of a retroviral 
particle is shown in Figure 2 (11).  
      Usually retroviruses do not lyse the host cells, and thus integration allows a long-
term association between the virus and the host cell. When a germ cell is infected by a 
retrovirus, colonization of the germ line by the virus is possible. Such inherited 
proviruses are called endogenous retroviruses (ERVs), and they provide evidence of 
ancient retroviral infections dating back many millions of years (10).  
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Figure 2. Schematic structure of a retroviral particle. Reprinted from reference (11) 
under the open access policy of BioMed Central.
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      Human endogenous retroviruses (HERVs) were first discovered in the 1980s (12). 
They are believed to have become integrated into the human genome around 35 million 
years ago via infection of the germline, which is supported by the fact that most HERVs 
appear to be ancient and are found in both Old and New World monkeys (this suggests 
that the first integration happened before the divergence of New World and Old World 
monkeys), and have been sustained there as vertically transmitted proviruses since that 
time (13, 14).  
      HERVs represent about 8% of the human genome and are widely dispersed (15). 
However, the majority of HERVs are incomplete, and in most cases HERVs are inactive. 
As most retroviral infections could be harmful to the host cells, evolutionary selection 
ensures that HERVs are disabled by mutations that prevent expression of some or all 
proviral genes during evolution. In most cases, almost the entire proviral genome was 
excised as a result of recombination of the two long terminal repeats (LTRs), and only a 
single (solitary) LTR was left. Even if the viral genome persists, other mutations, such as 
smaller deletions, frame shifts and premature stop codons, could prevent the expression 
of functional proteins from most HERV loci (16). In addition, epigenetic mechanisms 
including hypermethylation and histone modifications provide a further mechanism for 
silencing HERV provirus expression (16-18).  
      The genome of HERVs is composed of gag, pro, pol, and env genes. The gag gene 
codes for the structural matrix (MA), capsid (CA), and nucleocapsid (NC) proteins, the 
pro gene codes for protease (PR) protein, the pol gene codes for the enzymes of RT and 
integrase (IN), and the env gene codes for the envelope surface (SU) and transmembrane 
(TM) proteins. The retroviral genome is flanked by two LTRs that regulate viral gene 
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transcription. Each LTR contains unique 3’ (U3), repeat (R) and unique 5’ (U5) 
elements. The genomic structure of HERVs is illustrated in Figure 3. (19) 
      According to the mechanism of reverse transcription, the two LTRs should be 
identical. However, with time, they could undergo divergence due to various mutations 
acquired during cellular DNA replication, so the divergence between the two LTRs could 
be used as a molecular clock to understand the evolutionary radiation of the HERV 
family. In addition, multiple copy numbers of solitary LTR elements of the HERV-K 
family have been identified as being unique to humans. Therefore, solitary LTR elements 
could provide valuable information regarding the evolutionary history of retroelements 
within the primate genome (19). This information indicates that analysis of HERV LTRs 
can be used to determine the timeframe of HERV integration. 
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1.1.2 HERV classification and nomenclature 
      Based on the degree of pol sequence homology, retroviruses can be divided into 
several groups. HERVs belong to the beta-, gamma-, or spuma- retrovirus groups. No 
sequences with homology to delta- or lenti- viruses have been found in the human 
genome, although endogenous lentivirus genomes were discovered in basal primates, 
such as owl monkeys and macaques (10, 20).  However, HTLVs, members of delta-
retrovirus group, do share some common characteristics with certain HERVs, and these 
HERVs also exhibit splicing patterns comparable to the splicing in the more complex 
exogenous retroviruses (21). A phylogenetic tree has been created for human endogenous 
retroviruses as shown in Figure 4. 
      In general, gamma-retroviruses represent most HERV families. They have the largest 
genomic fraction (22) and are murine leukemia virus (MLV)-like (21). Beta-retroviruses 
contain the HERV-K elements and older retroviral families (23), and are murine 
mammary tumor virus (MMTV)-like (also often named human MMTV-like viruses, 
HML)(21). Spuma-retroviruses contain the oldest recognizable HERV elements (15). 
      HERVs can be further classified and named using the single letter amino acid code 
for the tRNA specificity of the primer binding site used to initiate reverse transcription. 
Thus, HERV-W would use a tryptophan tRNA if it were an infectious virus, and HERV-
K would use lysine (16). To date, 31 HERV families have been identified and are named 
according to the tRNA used to prime reverse transcription. However, based on sequence 
homology, HERVs can be grouped into 80 distinct families (24). An overview of 
representative HERV families is presented in Table 1. 
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      The conventional HERV classification and naming scheme may cause some 
problems, as it becomes inadequate when two HERVs are found to use the same tRNA 
(25). In addition, in some cases, the primer binding site sequence was not available when 
novel elements were first discovered, and thus they were named based on neighboring 
genes (e.g., HERV-ADP), clone number (e.g., HERV-S71) or amino acid motifs (e.g., 
HERV-FRD). Additional designations based on the probe used for cloning (e.g., HERV-
HML) and sub-divisions based on the degree of sequence identity in RT or phylogenetic 
reconstructions (e.g., HERV-K(HML-2)) have also been used. More recently, 
phylogenetic methods have been used to define different groups of HERV sequences 
(10). 
      The copy number of a specific type of HERVs in human genome varies greatly, from 
a single copy (eg, HRES-1), to 1000 copies (eg, HERV-H). The distribution of HERV 
sequences is found most concentrated in chromosomes Y, X, 4 and 20 (12).  
1.1.3 Normal physiological effects of HERV  
      Among all the ERV members, only a few elements may still be infectious in some 
host species, and the reason may be that they have been recently integrated into the 
genome of their host and they are still able to replicate and integrate new proviral copies 
within the germline. Koala endogenous retrovirus is an unique example, because it is not 
only threatening the species with extinction, but also it is an example of an infectious 
retrovirus that is currently undergoing endogenization (21). Other examples of these 
infectious ERVs are endogenous jaagsiekte sheep retrovirus (enJSRV), causing lung 
cancer in sheep; feline leukemia virus, causing leukemia and lymphomas in cats; MLV, 
causing leukemia in mice; and MMTV, causing breast cancer in mice (16, 21). However, 
12 
 
in humans, infectious HERVs have not been found yet (10, 16, 21), although a single 
cycle infectivity has been demonstrated by ‘HERV-KCON’, a reconstituted clone of 
human-specific HERV-K(HML-2), the youngest and the most active group of HERV-K 
elements (26). 
      As the majority HERVs are inactive in normal conditions, it was widely held that 
HERVs were ‘junk’ DNA ‘fossils’ of ancestral infections by exogenous retroviruses (14, 
16, 24). However, the fact that HERVs represent such a large portion of the human 
genome makes it less compelling that HERVs are really all ‘junk’. Conservation of 
HERVs in the human genome through evolution implies a positive evolutionary selection 
exerted by the host because HERVs may have introduced some beneficial effects to the 
host (14, 27). Several such effects have been proposed, as shown below. 
      First, HERVs may play a major role in shaping our genome by increasing its 
plasticity, and in the evolution of gene regulation networks. Some sequences of HERVs 
are targets for genomic rearrangements, and thus could contribute to the shaping and 
plasticity of the genome (28). LTR elements of HERVs contain numerous regulatory 
sequences, including effective promoters, enhancers, polyadenylation signals, and 
transcription factor binding sites, and these LTRs could also modulate transcriptional 
regulation, which contributed to primate evolution (14, 19). Examples of the roles played 
by HERVs in changing the genetic landscape include: the LTR of HERV-E is used as an 
alternative promoter for the endothelin B receptor and apolipoprotein C-I genes in 
humans; the HERV-K LTR promotes alternative splicing and encodes the 67 carboxy-
terminal amino acid residues in human leptin receptor protein; insertion of the HERV-H 
LTR provides the polyadenylation signals to human HHLA2 and HHLA3 genes; and 
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consensus sequences of HERV LTRs contain multiple binding sites for transcription 
factors such as p53, CTCF, Pou5F1-Sox2, and ESR1 (19). 
      Second, some HERV envelope (Env) proteins  likely play important roles in placenta 
formation. High expression levels of HERV-W and HERV-FRD Env proteins, named 
syncytin-1 and syncytin-2, respectively, as well as other retrovirus Env proteins, are 
detected in syncytiotrophoblasts, but not in cytotrophoblasts. These retrovirus Env 
proteins are anchored in the lipid bilayer of cell surface membranes, and exhibit cell-cell 
fusogenic activity. So these HERV Env proteins probably contribute to the physiological 
placenta morphogenesis by mediating fusion of cytotrophoblasts to syncytiotrophoblasts. 
In addition, the known immunosuppressive property of syncytin-2 and other HERV Env 
proteins (although not syncytin-1), suggests that these HERV Env proteins may 
contribute to prevent allogeneic rejection of the fetus at the fetal multinucleated villous 
syncytiotrophoblast layer, and HERVs may therefore be instrumental in safeguarding 
placental morphogenesis, physiology and fetal–maternal tolerance (14).  
     Third, HERVs can protect the host against exogenous virus infection, which is 
potentially oncogenic or immunosuppressive via interference with their receptors or the 
formation of antisense mRNA; this inhibitory interference is a general feature in animal 
retrovirology. For example, HERV-W Env glycoproteins can confer cellular resistance to 
superinfection by exogenous retroviruses as shown in vitro (12, 14).  
      Finally, HERV-encoded proteins may help the host fight against cancer. HERV-E is 
activated in a proportion of renal cancer cells, and was shown to provide target antigens 
recognizable by cytotoxic T-cells from donors after allogeneic hematopoetic stem cell 
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transplantation, which led to complete (10%) or partial (30%) tumor regression in 
patients (14). Another example is HERV-K Env (Kenv) protein, which could trigger both 
serologic and cellular immune responses, leading to the killing of HERV-K expressing 
cancer cells (29, 30). 
1.1.4 HERVs and human disease 
      Considering the disease-inducing properties of exogenous human retroviruses, it’s 
not surprising that HERVs also have detrimental effects (14). As discussed above, the 
majority of HERVs are silent under normal conditions, however, they become 
transcriptionally and even translationally active under altered physiological conditions, 
and show close association with some human diseases. These diseases include: male 
infertility (10, 19); autoimmune diseases such as rheumatoid arthritis, psoriasis, systemic 
lupus erythematosis, and Sjögren’s syndrome (21); neuropathogenic diseases such as 
multiple sclerosis and schizophrenia(21); and in particular, multiple cancers such as 
breast cancer and melanoma. 
      The association between HERVs and human cancer has been proposed for decades 
(14). An increased expression of HERVs in different tumors has been reported by many 
groups (Table 2), and this upregulation is not biased to any particular type of cancer. The 
trend of cancer-specific upregulation seems to be true across a broad spectrum of HERV 
families (9).  
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      As mentioned earlier, while infectious and potentially oncogenic ERVs exist in some 
animal species, no evidence shows the existence of an infectious, horizontally 
transmissible HERV, although the possibility can not be excluded (14). Without this 
direct evidence, although the association between HERVs and human cancer has been 
widely acknowledged, the causal relationship between the two is still a mystery: it is still 
unknown whether activation of HERVs initiates/ promotes cancer development or is a 
result of altered gene regulation in cancer cells. However, there is accumulating evidence 
for HERV involvement in the process of carcinogenesis, and several potential 
mechanisms of the role of HERV in this process have been proposed (9, 14, 28, 31). 
      First, HERV retrotransposition, HERV-mediated recombination, and epigenetic 
regulation of HERV LTRs have the potential to enhance oncogene expression or inhibit 
the expression of tumor suppressor genes, leading to the transformation of host cells. 
Furthermore, recombination between the thousands of HERV loci may lead to gain-of-
function sequences of HERVs, and thus to the generation of an infectious retrovirus. 
      Second, some HERV-coding proteins may play the role of oncoprotein. Two small 
accessory HERV-K proteins, Rec and Np9, which are products of alternative splicing of 
the env gene, have demonstrated oncogenic properties and shown direct involvement of 
HERV proteins in malignancy. 
      HERV may also indirectly facilitate cancer development by the immunosuppressive 
function of its Env proteins. This immunosuppression may be beneficial in 
syncytiotrophoblasts at the fetal-maternal interface (the syncytin case), while it may be 
detrimental to the immune surveillance of tumors. 
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1.2  HERV-K function in multiple human cancers 
1.2.1 The HERV-K family 
      HERV-K was first discovered in the late 1970s as ‘‘Human Teratocarcinoma- 
Derived Retroviruses’’ (HTDV), though its HERV attribution was not recognized at that 
time (14). In 1986, HERV-K10 was cloned and sequenced because of its sequence 
similarity with MMTV (this is where HML-2 (human MMTV-like 2), another name of 
HERV-K, arose from), and it was the first time that the whole genome sequence of a 
HERV-K provirus became known (16, 32). 
      Members of the HERV-K family are the youngest among all HERVs, and they 
integrated into the human genome between three and six million years ago (31). In 
particular, the youngest HERV-K, HERV-K113, which is located on chromosome 19, 
has been estimated to have entered the human genome since 200,000 to 2 million years 
ago (14, 33). It is estimated that there are about 1,000 copies of HERV-K including 
truncated forms and over 2,500 copies of solitary LTRs in the human genome, and more 
than 60 copies of HERV-K proviruses per haploid human genome have been further 
estimated (14, 19, 34).  
      Likely because of its later integration, HERV-K is the most complete and 
biologically active family, and contains retroelements showing polymorphic integration 
in the human genome (10, 16, 19, 31). Several HERV-K proviruses preserve functional 
full-length open reading frames (ORFs) coding for all structural, regulatory and 
enzymatic viral proteins, and HERV-K is the only known HERV family with this feature 
(14, 31). Moreover, it was stated that “HERV-K113 is an excellent candidate for an 
endogenous retrovirus that is capable of reinfecting humans today”(35), and this in turn 
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suggests that an infectious HERV-K would be the most likely candidate for the discovery 
of oncogenic retrovirus (14). 
      There are two forms of HERV-K: type I and type II HERV-K proviruses, as 
described in Figure 5. HERV-K10 belongs to the type 1 proviruses, containing a genome 
of ~9.2 kb, and HERV-K113 belongs to type II proviruses, contained an additional 292-
bp sequence at the boundary of the pol and env genes (16, 32). So the length of HERV-K 
genome ranges from ~9.2 kb to ~9.5 kb. The type II HERV-K is considered as the 
prototype, and it could express the accessory protein Rec (36). In type I HERV-K, the 
292 bp deletion at the pol-env boundary leads to the fusion of the pol and env genes, the 
absence of the Rec, and instead the presence of another accessory protein Np9. However, 
members of both types could contain all the ORFs required for retroviral replication (16). 
      Abundant studies have been reported on the relationship between HERV-K and 
human diseases, such as rheumatoid arthritis and psoriasis (16, 24). However, the hotspot 
of these studies is the association between HERV-K and cancer. HERV-K is thought to 
be transcriptionally silent in normal cells, and become active after malignant 
transformation (14, 31), except in the case of brain tumor (37). High expression of 
HERV-K has been detected in different human cancers, which seems to be tumor-
specific (absent or of low expression in normal or adjacent uninvolved tissues) (9, 31). 
As described earlier, a causal relationship between HERV-K and cancer is still unknown, 
but it has been thought that activation of HERV-K may initiate or maintain 
carcinogenesis (31).
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      In particular, HERV-K can express two accessory viral proteins, Rec and Np9, which 
are not found in other HERVs, and the two proteins are believed to have oncogenic 
potential (14). Rec, originally named as cORF, is a functional homologue of the HTLV1 
Rex and HIV Rev, and is responsible for the nuclear export of un-spliced or single-
spliced viral mRNA into the cytoplasm (14, 38). Rec was capable of transforming Rat-1 
(a non-tumorigenic rat fibroblast cell line) cells in vivo in nude mice (39), of contributing 
to germ cell tumor development in transgenic mice (40), and of promoting Raji (a human 
Burkitt's lymphoma cell line) xenograft tumor growth in NOD-SCID mice (41). Np9 is 
exclusively expressed in leukemia, breast cancer and germ cell tumors, but not in normal 
cells or cell lines (9, 14). Np9 is thought to act as oncoprotein in germ cell tumors (14, 
16), and recently it has been identified as a potent viral oncogene in human leukemia 
(41). Both Rec and Np9 could bind to the promyelocytic leukemia zinc finger protein 
(PLZF), which is known as a tumor suppressor, a transcriptional suppressor of the c-myc 
proto-oncogene, and a spermatogonial stem cell regulator. Co-expression of Rec and 
Np9 abolished transcriptional repression of the c-myc gene through binding to PLZF, 
leading to increased synthesis of c-Myc protein and proteins regulated downstream of c-
Myc such as p53, PCNA and IkBa (14, 39, 42). Furthermore, Np9 can bind to and 
directly interfere with ligand of numb protein X, a RING-Type E3 ubiquitin ligase, and 
thus interfere with the Numb/Notch pathway (43), which is essential for proliferative Ras 
signaling, and whose abnormal regulation is suggested to initiate germ cell tumor 
development by causing genetic instability (44). These observations collectively provide 
molecular mechanisms for the oncogenic potential of the two proteins. 
21 
 
      In addition, HERV-K virus-like particles have been detected in teratocarcinoma (16), 
breast cancer (45-47), melanoma (48), and lymphoma (47). However, an attempt to 
identify infectious HERV-K viral particles from melanoma was unsuccessful (49), and 
indeed no infectious HERV-K proviruses have been discovered to date (14, 16).  Two 
HERK-K provirus prototype constructs, Phoenix (50) and HERV-KCON (26), have been 
independently reconstituted by deriving a consensus sequence of HERV-K. The two 
constructs can generate viral particles infectious to both human and animal cells in vitro, 
and provide new tools for further study of the oncogenic effects of HERV-K in cancer 
(16). HERV-K virus-like particles have also been found in the blood of HIV-1-fnfected 
individuals (51).  
1.2.2 HERV-K and human breast cancer 
      Breast cancer is one of the most common cancer types and the second leading cause 
of cancer death among women in the US (31). It is estimated that 232,340 new cases of 
invasive breast cancer and 64,640 new cases of in situ breast cancer are expected to 
occur among women during 2013 (an estimated 2,240 new cases of breast cancer are 
expected to be diagnosed in men), with an estimation of 40,030 breast cancer deaths 
(39,620 women, 410 men) (52). So breast cancer represents one of the most serious and 
costly public health issues in the US (53). 
      Risk factors for breast cancer include being a woman, increasing age, weight gain 
after age 18, obesity, use of menopausal hormone therapy, physical inactivity and 
alcohol consumption. Risk is also increased by a strong family history of breast cancer. 
Inherited mutations in breast cancer susceptibility genes account for about 5-10% of all 
female breast cancers and an estimated 4-40% of all male breast cancers, while they are 
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very rare in the general population (much less than 1%). Most of these mutations are 
located in BRCA1 and BRCA2 genes (54).  
      Human breast cancer is a highly heterogeneous cancer type of about 20 
morphologically distinct subtypes with substantially different molecular and/or 
biochemical signatures, clinical courses, and prognoses (55). This high heterogeneity 
suggests different etiologies of breast cancer, such as inherited mutations and 
environmental factors, and many studies have been providing substantial, but not 
conclusive, evidence that breast cancer might be caused by EBV, MMTV, HPV (56-58) 
and HERV-K (31). 
      The association between breast cancer and HERV-K was first revealed by Ono et al. 
in 1987 (59), though the possibility of this association had been suggested by the same 
group in 1986 (32). They reported for the first time in the 1987 study that HERV-K 
genome expression could be stimulated by hormone treatment in vitro in the human 
breast cancer cell line T47D. In 1992, T47D was found to secrete retrovirus-like particles 
related to MMTV and with human endogenous origin in a steroid-dependent manner 
(60), and three years later, the sequence of HERV-K was identified from these virus-like 
particles (45). In 1998, the proviral structure and chromosomal location of the HERV-K 
from T47D particles was confirmed (61). 
      An endogenous DNA sequence with partial homology to MMTV was found in 
human breast tumors by Szakacs et al. in 1991 (62), but the identity of the DNA 
sequence was not confirmed. However, not until 6 years later were HERV-K transcripts 
(env) identified in malignant tissues and in peripheral blood of human breast cancer 
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patients for the first time, along with several other cancers, via RT-polymerase chain 
reaction (RT-PCR) by Willer et al. (63). 
      In 2001, our group reported that type I Kenv transcripts from multiple loci are 
frequently expressed in human breast cancer, but not in normal or uninvolved breast 
epithelial cells, and that some clones of these transcripts contained no premature 
termination codons and were capable of expressing Kenv protein (64). Two years later, 
our group also observed the expression of type II Kenv transcripts in human breast 
cancer, with a significantly higher level than in normal breast tissues; we also 
investigated the splicing patterns of both types of HERV-K, and found that both types 
expressed spliced subgenomic env transcripts, which are also tumor-specific. In all, these 
studies suggest that multiple HERV-K endogenous retroviral element splice variants 
could be novel breast tumor markers (65).  
      In 2008, Maya Golan et al demonstrated the existence of active HERV-K RT in 
human breast cancer, and found its significant correlation with poor prognosis for 
disease-free patients and their overall survival, suggesting that HERV-K RT might be 
expressed in early malignancy and might serve as a novel prognostic marker for breast 
cancer (66). Similar findings regarding Kenv protein have been reported by our group in 
2011.  We found that the expression of Kenv protein in breast cancer patients is 
associated with markers of disease progression and poor disease outcome, thus 
suggesting that HERV-K expression may enhance metastasis, and that Kenv protein is a 
novel candidate prognostic marker for breast cancer (67). HERV-K elements have also 
been discovered in the plasma of people with breast cancer (47).   
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      To assess the potential of HERV-K as a biomarker for immunotherapy of breast 
cancer, we investigated the expression of Kenv protein in human breast cancer, and 
reported in 2008 that Kenv protein is expressed in 88% of breast cancer tissues but not in 
normal breast tissues, and that it can trigger both humoral and cellular immune 
responses. We also produced HERV-K-specific cytotoxic T lymphocytes (CTLs), which 
were capable of lysing target cells expressing Kenv protein in breast cancer patients but 
not in normal female controls without cancer. These findings suggest that Kenv proteins 
are capable of acting as tumor-associated antigens, activating both T-cell and B-cell 
responses in breast cancer patients (29). Furthermore, in 2012 we reported that 
monoclonal antibodies (mAb) specific to Kenv protein could inhibit growth and induce 
apoptosis of breast cancer cells in vitro, and significantly inhibit breast tumor growth in 
vivo in a mouse xenograft model, suggesting that mAbs against Kenv protein have 
potential as novel immunotherapeutic agents for breast cancer therapy (30). 
1.2.3 HERV-K and melanoma 
      Melanoma is the most serious form of skin cancer. For melanoma patients, when 
distant metastases occur the prognosis is very poor, with median survival of less than 1 
year and less than 10% of patients alive at 5 years (68). It accounts for the majority of 
skin cancer deaths, although accounting for less than 5% of all skin cancer cases. In 
2013, an estimated 76,690 new cases of melanoma will be diagnosed in the US and about 
12,650 patients will die from the disease. Major risk factors for melanoma include a 
personal or family history of melanoma and the presence of atypical or numerous (more 
than 50) moles.  Other risk factors include sun sensitivity and a history of excessive sun 
exposure (54).  
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      The first evidence showing the association between HERV-K and melanoma was 
reported by Schiavetti et al. in 2002. In their study, a human endogenous retroviral 
sequence termed HERV-K-MEL, which shows homologies with HERV-K and can 
encode an antigen recognized on melanoma by CTLs, was discovered, and was 
considered for use in vaccination (69). 
      As early as 1974, particles resembling retroviruses, which were called RNA tumor 
viruses at that time, were found in human melanoma (70). However, not until 2003 were 
retrovirus-like particles with sequences homologous to HERV-K discovered by Muster 
et al. in human melanoma cells (48). These particles exhibit RT activity and contain 
mature forms of the Gag and Env proteins. In addition, the pol gene and Gag, Env, and 
Rec proteins are expressed in human melanomas and metastases but not in melanocytes 
or normal lymph nodes, suggesting that expression of retroviral genes/ proteins and 
production of retroviral particles is activated during development of melanoma (48). 
Later, Büscher et al. demonstrated that these particles contain deletions and are 
noninfectious.  They also found antibodies against HERV-K, for the first time, in 
melanoma patients, and concluded that melanoma is associated with enhanced 
expression of HERV-K (36). The same group later investigated the expression of Rec, 
Np9, and TM in melanoma cells, and came to the conclusion that they had expression 
patterns similar to those seen in teratocarcinoma cell lines (71).   
      To search for a melanoma marker, Humer et al. identified an immunodominant 
peptide located in the Env protein of HERV-K from bioinformatic screening, and their 
results suggest the potential of the peptide as a target for diagnosis and immunotherapy 
(72). Silvia Hahn et al studied the serological response to HERV-K Gag and Env protein 
26 
 
in patient sera to elucidate the prognostic relevance of serological anti-HERV-K 
reactivity in melanoma patients and correlate with survival probability.  Indeed they 
found the correlation, suggesting that humoral anti-HERV-K immune response may 
provide additional prognostic information for melanoma (73). 
    Using RNA interference (RNAi) specific to HERV-K, two groups revealed potential 
roles of HERV-K in melanoma. Oricchio et al. found that with down-regulated HERV-K 
expression by RNAi in the melanoma cell line A375, the in vivo tumorigenic potential of 
the interfered cells was reduced after inoculation of the cells in nude mice, although the 
in vitro cell proliferation and differentiation remained unchanged (74).  Serafino et al. 
found that when exposed to stress conditions, human melanoma cells undergo a 
transition in vitro from adherent to a more malignant, non-adherent phenotype, with an 
increased proliferative potential, and that his transition was accompanied by the 
activation of HERV-K and massive production of viral-like particles. In addition, down-
regulation of HERV-K expression by RNAi prevents the transition in low serum (75). 
These results implicate HERV-K as playing a critical role at least during melanoma 
progression.  
      Environmental factors have also been used to study the association between HERV-
K and melanoma. UV irradiation can induce differential expression of rec and np9 
transcripts in primary human melanocytes and melanoma cell lines (76); it can also 
induce a significant activation of HERV-K pol gene as well as an enhanced expression of 
Kenv protein in melanoma cell lines, but not in non-melanoma cells (77). These findings 
indirectly suggest the involvement of HERV-K in melanoma. 
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      It is not fully understood how HERV-K expression is regulated in melanoma, and 
recently some studies have been addressing this question. Stengel et al. investigated the 
epigenetic regulation of HERV-K in melanoma, and found that increased HERV-K 
expression in melanomas may be due to increased promoter activity and demethylation 
of the 5'LTR (78). Li et al. found that in melanoma cells, expression of HERV-K 
correlates with status of MEK-ERK and p16INK4A-CDK4 pathways in melanoma cells, 
and inhibition of MEK or CDK4, especially in combination, reduced Kenv expression 
(79). Katoh et al. found that MITF-M, a melanocyte/melanoma-specific isoform of 
microphthalmia-associated transcription factor (MITF), could activate the pigmented cell 
lineage-specific function of HERV-K LTR, leading to the high-level expression of 
HERV-K in malignant melanoma (80). These findings provide some molecular 
mechanisms for the regulation of HERV-K expression in melanoma.    
      Most recently, according to analysis of HERV-K loci transcription in melanoma, 
unlike Gag, the Env-coding loci with ORFs are only transcribed in melanoma, but not in 
normal melanocytes, suggesting the involvement of Env protein in melanoma (81). 
Huang et al. observed that when HERV-K expression was reduced using RNAi and anti-
Kenv monoclonal antibodies, dramatic reduction of intercellular fusion of cultured 
melanoma cells occured, revealing the novel fusogenic function of Kenv protein in 
melanoma cells (82). These findings suggest that Kenv protein could play important 
roles in melanoma. 
1.2.4 HERV-K and human pancreatic cancer 
      Pancreatic cancer is one of the most deadly cancer types. In the US, pancreatic cancer 
is the 10th most common cancer among men and the 9th most common among women, 
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and it accounts for about 7% of all cancer deaths and ranks fourth as a cause of cancer 
death among both men and women. In 2013, an estimated 45,220 new cases of 
pancreatic cancer will be diagnosed nationwide, with an estimation of about 38, 460 
pancreatic cancer deaths. Most pancreatic cancer patients will die within the first year of 
diagnosis, and the five-year survive rate is only 6% (54).   
      Pancreatic cancer is considered as a silent killer because early pancreatic cancer often 
does not cause symptoms, and the symptoms at later stages are usually non-specific and 
varied, resulting in late diagnosis and consequently an exceptionally low survival rate. 
The lack of progress in primary prevention, early diagnosis, and treatment underscores 
the need for additional efforts in pancreatic cancer research. Since pancreatic cancer is so 
deadly, any new agents that can improve patient survival by improving its detection or 
treatment could revolutionize clinical practice (54).  
      There has been no direct evidence linking HERV-K and human pancreatic cancer. 
However, when seeking to identify novel cancer testis antigens in pancreatic cancer for 
immunotherapy applications, Schmitz-Winnenthal et al. found that HERV-K-MEL is 
expressed in 23% of malignant, but not in non-malignant, pancreatic tissues (83). 
Considering the fact that HERV-K-MEL is a partial Kenv sequence, this study could 
implicate that Kenv be specifically expressed in human pancreatic cancer. In fact, our 
group recently investigated HERV-K expression in human pancreatic cancer. In our 
studies, using RT-PCR and sequence analysis, Kenv mRNAs were found to be expressed 
in seven pancreatic cancer cell lines as well as in 80% of pancreatic cancer xenograft 
biospies, but not in HPDE-E6E7 nonmalignant cells. The expression profile of Kenv 
proteins, characterized via using an anti-HERV-K mAb, revealed HERV-K expression in 
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pancreatic cancer cells and specimens but not in HPDE-E6E7 cells or matched adjacent 
uninvolved normal tissues. Higher RT activity was observed in culture media obtained 
from Panc-2, Panc-1, and Colo-357 cells than in media from other pancreatic cancer cell 
lines and HPDE-E6E7 cells. Furthermore, Kenv or gag mRNA expression, as well as the 
titer of antibody against Kenv SU or Np9, was significantly higher in sera obtained from 
pancreatic cancer patients than from normal donors. Our data indicate that HERV-K 
genes are transcribed, translated, and able to produce viral particles in some pancreatic 
cancer cell lines and sera obtained from pancreatic cancer patients. Our results also 
demonstrate that HERV-K viral protein or viral particles have characteristics of tumor-
associated antigens, and are potentially useful targets for detection, diagnosis and 
immunotherapy of pancreatic cancer (manuscript submitted for publication).  
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Chapter 2 Statement of Objectives 
      Although published data have suggested the tight association between HERV-K 
expression and multiple human cancers, the causal relationship between the two is still 
unclear, and it is even uncertain which HERV-K gene/ protein could play a critical role 
in this association. However, the transition of melanoma cells under stress could not be 
accomplished with down-regulation of HERV-K, suggesting the critical involvement of 
HERV-K in melanoma transformation. 
      As mentioned above, expression of Kenv protein has been observed in multiple 
human cancers, including breast cancer, melanoma and pancreatic cancer, but not in 
normal tissue or normal cell lines. In addition, Kenv protein can trigger a serologic 
response in patients with all the three of these cancer types. Importantly, Kenv protein 
antibodies exhibit antitumor potential in targeting breast tumors, indicating that Kenv 
may play an important role in carcinogenesis or tumor progression. However, the actual 
role of Kenv protein in cancer is still to be confirmed. Based on all the previous findings, 
I hypothesized that the Kenv protein may be involved in the processes of 
proliferation, migration and invasion associated with multiple human cancers, and 
that the Kenv protein may play an important functional role as an oncogene in 
multiple human cancers. In this project, I studied the role of Kenv protein in human 
breast cancer, pancreatic cancer and melanoma, using both over-expression and 
knockdown approaches, and tried to address the mechanism underlying the role of Kenv. 
To address my hypothesis, I proposed three Specific Aims:  
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1. To determine the effect of knockdown of Kenv protein using RNAi on human 
cancer cell growth and tumorigenic potential. An Kenv-specific shRNA (shRNAenv), 
as well as a corresponding scrambled control shRNA (shRNAc), was constructed in a 
shRNA-expressing lentivector and stably transduced into multiple human cancer cell 
lines. The mRNA and protein levels of Kenv were evaluated after transduction, and the 
proliferation, colony formation and cell migration potential of the transduced cells were 
determined in vitro and in vivo. 
2. To characterize Kenv protein expression and function in stably-transfected 
human cell lines.  A lentivector that can express Kenv protein in mammalian cells was 
constructed (pLVX-Kenv), and the empty lentivector was used as control (pLVX). The 
pLVX-Kenv or pLVX vector was stably transduced into the premalignant human breast 
epithelial cell line MCF10AT, as well as cancer cell lines that included MCF-7 and 
SKBR-3. The mRNA and protein levels of Kenv were evaluated after transduction, and 
the proliferation, colony formation and migration potential of the transduced cells were 
determined in vitro and in vivo. 
3. To determine the role(s) of Kenv protein in mechanistic pathways involved in 
multiple human cancers. Xenograft HERV-K knockdown tumors growing in 
immunodeficient mice were subjected to RNA Seq analysis, and the results were 
analyzed by Ingenuity Pathway Analysis (IPA) for the presence of gene networks that 
would explain the changes in gene expression that we observed in the tumors. Some 
preliminary validation of the IPA results was done, and further work needs be carried out 
to complete the verification of changes in expression of signaling pathway proteins in 
response to HERV-K knockdown in these cancer cells and tumors. 
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Chapter 3 Materials and Methods 
3.1 Cell lines and animals 
      Human breast cancer cell lines SKBR-3, MCF-7 and MDA-MB-231, human 
pancreatic cancer cell lines Panc-1 and Panc-2, and human melanoma cell line A375 and 
SK-MEL28 were obtained from the American Type Culture Collection (ATCC, 
Manassas, VA). The human breast cancer cell line MDA-MB-435 eB1, which was 
established from MDA-MB-435 by transfecting with c-erbB-2 cDNA, and which 
overexpresses v-erb-b2 erythroblastic leukemia viral oncogene homolog 2, neuro/ 
glioblastoma derived oncogene homolog (avian) (ERBB2), was a kind gift from Dr. 
Michael Rosenblum (The University of Texas MD Anderson Cancer Center, Houston, 
TX). The premalignant human breast cell line MCF-10AT, an H-Ras-transformed variant 
of the human breast epithelial cell line MCF-10A, was purchased from The Barbara Ann 
Karmanos Cancer Institute (Detroit, MI). 293TN, which is a variant of 293T and is  
optimized for optimized for  pseudoviruses production, was purchased from System 
Biosciences (SBI, Mountain View, CA). 293FT, similar to 293TN, was a kind gift from 
Dr. Dean Tang (The Virginia Harris Cockrell Cancer Research Center at The University 
of Texas MD Anderson Cancer Center, Smithville, TX). MCF-7, MDA-MB-231 and 
SK-MEL-28 were cultured in Roswell Park Memorial Institute (RPMI)-1640 medium 
supplemented with 10% FBS, 100 U/ml penicillin and 100 μg/ml streptomycin; MCF-
10AT was cultured in Dulbecco’s Modified Eagle Medium: Ham’s Nutrient Mixture F12 
(DMEM:F12) medium supplemented with 5% horse serum, 100 U/ml penicillin, 100 
μg/ml streptomycin, 10 μg/ml insulin, 20 ng/ml epidermal growth factor and 0.5 μg/ml 
hydrocortisone; all other cell lines were cultured in DMEM medium supplemented with 
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10% FBS, 100 U/ml penicillin and 100 μg/ml streptomycin. 
      Immunocompromised nude and NOD-SCID gamma (NSG) mouse stains were used 
in xenograft tumor model studies. Nude mice were purchased from NCI at Frederick 
(Frederick, MD). NSG mice were a generous gift from Dr. Dean Tang. 
3.2 Lentivector construction and packaging 
     A short hairpin RNA (shRNA) sequence targeting the HERV-K env (GenBank No. 
M14123.1) SU region (shRNAenv) and a matched scrambled shRNA sequence serving 
as negative controls (shRNAc) were designed using the Invitrogen Block-iT RNAi 
Designer. For each shRNA, two partial-matching oligonucleotides, both containing the 
shRNA sequence, were designed, synthesized, annealed and then cloned into the 
pGreenPuro™ vector (SBI) as shown in Figure 6. The shRNA-expressing lentiviral 
particles were packaged using a pPACKH1 Lentivector Packaging Kit (SBI), and then 
the virus particles were titered using 293TN cells, following the manufacturer’s manual. 
      A Kenv-expressing vector (pLVX-Kenv) was constructed from lentivector pLVX-
dsRed-Monomer-C1 (pLVX) (Clontech Laboratories, Mountain View, CA), as shown in 
Figure 7. cDNA of a full-length Kenv was de novo synthesized based a sequence 
obtained from plasma of a breast cancer patient.  The sequence, which showed high 
homology to HERV-K50A provirus (GenBank Accession Number: DQ112146), was 
then cloned into the lentivector by Biomatik (Cambridge, Ontario, Canada). The Kenv-
expressing lentiviral particles were then packaged and titered in 293FT cells according to 
the instructions of the manufacturer of the vector. The lentiviral particles generated from 
pLVX vector were used as negative controls. 
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Figure 6. Construction of shRNA-expressing lentivector. A shRNA sequence targeting 
the HERV-K env SU region (shRNAenv) and a matched scrambled shRNA sequences 
serving as negative controls (shRNAc) were cloned into the lentivector vector 
pGreenPuro at EcoRI and BamH I restriction enzyme sites..
HERV-K Env 
shRNAenv 
  shRNAv 
SU TM 
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Figure 7. Construction of Kenv-expressing lentivector pLVX-Kenv. A Kenv sequence 
obtained from plasma of a breast cancer patient was cloned into lentivector pLVX-
DsRed-Monomer-C1 (pLVX) at BsaI (insert)/EcoRI (vector) and XmaI restriction 
enzyme sites. Lentivector pLVX was used as negative control. 
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3.3 Lentivector transduction 
      100,000 cells were seeded into each well and grown in 6-well plates and then 
transduced with the lentiviral particles at a multiplicity of infection (MOI) of 40. After 
three days, cells were transferred into T25 flasks and cultured in media containing 0.2 
μg/ml of the selective drug puromycin. After at least two weeks post transduction, the 
stably-selected cells were used in various assays. 
3.4 RT-PCR and qRT-PCR 
      RNA was isolated from cells or tumor biopsy specimens using TRI reagent (Sigma-
Aldrich, St. Louis, MO), and cDNAs of Type 1 and Type 2 Kenv SU were amplified by 
RT-PCR as described previously (64, 65).  The cDNA of β–actin was amplified as a 
positive control and used to confirm equal loading of samples. Ready-to-Go You-Prime 
First-Strand Beads (GE Healthcare, Pittsburgh, PA) were used to synthesize cDNA from 
10 µg RNA, and 1 µg RNA was used in each PCR reaction. Primers K10 OS and K10 
OAS were used to amplify cDNA of Type 1 Kenv SU, and primers K22 OS and K10 
OAS were used to amplify cDNA of Type 2 Kenv SU (Table 3). The PCR was carried 
out on a DNA Engine (PTC-200, Bio-Rad) thermocycler using the following program: 
95 oC for 3 min, 35 cycles of 94 oC for 1min, 55 oC for 1min, 72 oC for 1 min, and a final 
10 min extension at 72 oC. 
      The mRNA levels of Kenv in different cell lines or xenograft tumors were quantified 
and compared by quantitative RT-PCR (qRT-PCR) using Kenv-specific primers and 
probes as described previously (65) (Table 3). Generally, qRT-PCT was carried out 
using the TaqMan® One-Step RT-PCR Master Mix Reagents Kit (Life Technologies, 
Grand Island, NY)  in a 7900HT Real-time PCR instruments (Life Technologies, Grand 
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Island, NY) using the following program: 48 °C for 30 minutes, 95 °C for 15 minutes, 
and then 40 cycles of 15 seconds at 95 °C and 1 minutes at 60 °C. After the qRT-PCR 
reaction was completed, the mRNA levels of Kenv in different RNA samples were 
compared using the delta-delta Ct method, with normalization to that of an endogenous 
control, glyceraldehyde-3-phosphate dehydrogenase (GAPDH, Life Technologies, Grand 
Island, NY).  
      To validate the RNA Seq results, a two-step qRT-PCR was carried out. After cDNA 
synthesis using the RTG beads as described above, the cDNAs of shRNA transduced 
cells were used as template, and the genes involved in the mevalonate pathway were 
tested using the SYBR® Green PCR Master Mix (Life Technologies, Grand Island, NY) 
and the primers described in Table 3.  
3.5 Immunoblot analysis 
      Total protein lysates of cells were used for immunoblot analysis (~50 µg of protein 
per lane) as described previously (29, 30). Anti-Kenv mAb (6H5) (~1 μg/ml) and anti-
actin (ACTB) antibodies (1:200 dilution; University of Iowa, Iowa City, IA) were used 
as primary antibodies, with anti-mIgG-horseradish peroxidase conjugates (1:5000 
dilution; Sigma-Aldrich, St. Louis, MO) serving as the secondary antibody.  
3.6 Cell proliferation 
      1 x 104 cells/well were plated in complete medium in a 24-well plate and incubated at 
37 °C. Cells were then trypsinized at different time points, and cell proliferation rates 
were measured by counting number of viable cells using the trypan blue dye exclusion 
method. 
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Primers Sequences 
For RT-PCR: 
  K10 OS 5′-AGAAAAGGGCCTCCACGGAGATG-3’  
  K10 OAS 5′-ACTGCAATTAAAGTAAAAATGAA-3’  
  K22 OS 5'-GTATGCTGCTTGCAGCCTTGATGAT-3’  
  Actin OS 5’-TGACGGGGTCACCCACACTGTGCC-3’ 
  Actin OAS 5’-CTAGAAGCATTTGCGGTGGACGAT-3’ 
For one-step qRT-PCR: 
  Kenv Forward 5'-ATTGGCAACACCGTATTCTGCT-3'  
  Kenv Reverseev 5'-CAGTCAAAATATGGACGGATGGT-3' 
  Kenv Probe 5'-FAM-ACACAGGGATCCACACGCCCTCTCTT-TAMRA-3'  
For two-step qRT-PCR 
  RPL32 Forward 5'-TTCCTGGTCCACAACGTCAAG-3' 
  RPL32 Reverse 5'-TGTGAGCGATCTCGGCAC-3' 
  ACAT2 Forward 5'-GCGGCGCGGACCAT-3' 
  ACAT2 Reverse 5'-CCTGGACAGGAACAGCAGCTA-3' 
  HMGCS1 Forward 5'-GGGCAGGGCATTATTAGGCTAT-3' 
  HMGCS1 Reverse 5'-TTAGGTTGTCAGCCTCTATGTTGAA-3' 
  HMGCR Forward 5'-GGCCCAGTTGTGCGTCTT-3' 
  HMGCR Reverse 5'-CGAGCCAGGCTTTCACTTCT-3' 
  MVD Forward 5'-TGAACTCCGCGTGCTCATC-3' 
  MVD Reverse 5'-CGGTACTGCCTGTCAGCTTCT-3' 
  IDI1 Forward 5'-TTTCCAGGTTGTTTTACGAATACG-3' 
  IDI1 Reverse 5'-TCCTCAAGCTCGGCTGGAT-3' 
  SQLE Forward 5'-CGTGCTCCTCTTGGTACCTCAT-3' 
  SQLE Reverse 5'-CGGTCAAGGCGGAGATTATC-3' 
  CYP51A1 Forward 5'-TGCAGCCTGGCTCTTACCA-3' 
  CYP51A1 Reverse 5'-AGCTCTGTCCCTGCGTCTGA-3' 
  DHCR24 Forward 5'-CAAGTACGGCCTGTTCCAACA-3' 
  DHCR24 Reverse 5'-CGCACAAAGCTGCCATCA-3' 
 
Table 3. Sequences of primers and probe used in RT-PCR and qRT-PCR assays. All the 
primer were synthesized by Integrated DNA Technologies (IDT, Coralville, IA), and 
probe was synthesized by Life Technologies (Grand Island, NY). The sequences of the 
primers used in the two-step qRT-PCR are obtained from reference (84).   
39 
 
3.7 Anchorage-independent colony formation assay (soft agar assay) 
      Anchorage-independent growth of lentivector-transduced cells was tested according 
to a published method (85). Briefly, 2 ml culture medium with 0.7% agar was first plated 
into each well of a 6-well plate. After the bottom agar solidified, each well received 
another 1 ml 0.35% agar in culture medium carrying 5, 000 cells. Colonies were counted 
after 2 to 3 weeks of incubation. 
3.8 Time-lapse wound-healing assay 
      shRNA transduced cells were plated in 6-well plates. Cells were cultured until 
reaching confluence, and then the confluent monolayer was scratched using a plastic 
pipette tip and replaced with fresh medium. Sequential and single images were acquired 
at different time points (up to 48 hours) and were assembled. 
3.9 Trans-well plate assay 
      For migration assay, 24-well plates with transwell permeable supports (Fisher 
Scientific, Hampton, NH) were used. Cells were trypsinized, counted and suspended in 
serum-free medium at a dilution of 2.5x 105/ml. 200 μl serum-free medium with 
suspended cells was placed into the upper chamber, and 750 μl complete medium was 
placed into the bottom chamber. The plate was incubated at 37 oC for 16-40 hours, until 
some cells attached and grew in the bottom chamber. The medium was removed and the 
chambers were washed twice with phosphate buffered saline (PBS). The cells were then 
fixed with  formaldehyde (3.7% in PBS, 1 ml/ well) at room temperature for 2 minutes, 
washed twice with PBS, and permeabilized with 100% methanol at room temperature for 
20 minutes. After fixation and permeabilization, the cells were washed twice, stained 
with Giemsa at room temperature for 15 minutes, washed twice again and rinsed with 
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PBS. The cells in the bottom chamber were counted as migrated cells under a 
microscope. 
      The invasion assay was carried out in a manner similar to the migration assay, with 
some modifications: Before the transwell plate was used, 100 μl Matrigel (BD 
Biosciences, San Jose, CA) was added to each upper chamber, and the plate was 
incubated at 37 oC overnight to allow gelling. After staining, adherent cells in the upper 
chamber were scraped off with cotton swabs, and the cells adhering to the bottom of the 
upper chamber were counted as invaded cells under a microscope. 
3.10 In vivo studies 
      To assess tumorigenesis and phenotypes of lentivector-transduced cells in vivo, 6-8 
week old female nude or NSG mice, were inoculated subcutaneously under the fourth 
mammary gland (the breast cell lines) or in the flank (all other cell lines) with 1 × 106 
cells transduced with shRNAenv or shRNAc to assess tumorigenesis and phenotypes of 
these cells in vivo. Tumors were harvested in accordance with IACUC animal welfare 
indications and compared by weight. H&E staining was used to provide histologic 
evidence of malignancy. RNAs and proteins were isolated from both groups and the 
expression of Kenv was determined by qRT-PCR/RT-PCR and immunoblot.  To 
determine the metastatic potential of shRNA transduced MDA-MB-231 and Panc-2 cells, 
lung tissues were collected post-mortem and cultured in the same media as parent cells. 
Metastatic MDA-MB-231 or Panc-2 cells isolated from lung were compared between the 
two groups. 
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3.11 RNA Seq analysis 
      For RNA Seq, the quality of isolated total RNA isolated from the xenograft tumors 
was verified on a Bioanalyzer 2100 (Agilent Technologies, Santa Clara, CA). RNA 
samples with an RNA Integrity Number above 8.0 were used in the RNA Seq 
experiment. cDNA libraries were synthesized from 100 ng input RNA using NuGen’s 
Ovation RNA Seq System (NuGEN Technologies, San Carlos, CA), following the 
manufacturer’s guidelines. After shearing the cDNA into 150-400 bp fragments on a 
Covaris S220 (Covaris, Woburn, MA), these fragments were ligated and indexed with 
Bioo Adapter 100 (Bioo Scientific, Austin, TX) on a SPRIworks Fragment Library 
System (Beckman Coulter, Brea, CA). The adapter-ligated cDNA fragments were size-
selected and cleaned up on SPRIworks, and quality checked by both Bioanalyzer and 
qPCR on a 7900HT Fast Real-time PCR System (Life Technologies, Grand Island, NY). 
Libraries from 6 RNA samples were pooled and hybridized to primers on a flow cell for 
cluster generation on an Illumina cBot (Illumina, San Diego, CA). A 76 nt paired-end 
run was performed on an Illumina HiSeq 2000. Sequencing data were transmitted to 
either an HP DL385 or HP DL585 computer server in real-time and stored in an HP 
P2000 data storage array on-site at MD Anderson – Science Park (Smithville, TX). For 
mRNA Seq data analysis, to rescue the reads over splice junctions, the sequenced reads 
were mapped to the mouse or human reference genomes by the splice junction aligner 
TopHat (86). The number of reads in each known gene from the RefSeq database (87) 
(mRNA Seq) were enumerated and the difference of read counts per gene between 
samples (i.e., differential expression) was statistically assessed by R/Bioconductor 
package edgeR (88) or DESeq (89). Networks of differentially expressed genes were 
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identified using Ingenuity Pathway Analysis (IPA; Ingenuity Systems, Inc., Redwood 
City, CA). 
3.12 Statistical analysis 
      All statistical tests were two-sided, and differences between variables with a P value 
of <0.05 were considered statistically significant. We used t-tests to analyze differences 
between treatment groups in cell culture experiments using GraphPad Prism 5. 
3.13 Ethics Statement: 
      All mouse experiments were approved by the Institutional Animal Care and Use 
Committees (IACUC, protocol number 01-04-00733) of the University of Texas MD 
Anderson Cancer Center. Mice were housed in a temperature-, humidity-, and light-
controlled room and fed a sterile regular diet. The ventilated caging housing system 
consists of a polycarbonate or polysulfone cage, a polycarbonate or polysulfone filter lid 
with woven-fiber filter media, and a stainless steel wire-bar lid.  The individual cages are 
maintained on a HEPA-filtered, ventilated, suspended cage-type rack.  Per institutional 
practice, the maximum mouse population per mouse cage is 5 adult mice of any size or 
age. For euthanasia, mice were placed in a chamber filled with CO2 and after breathing 
stopped and the mice were unconscious, euthanasia was completed by cervical 
dislocation. Tumors were excised on the final day of the study. The tumor tissues were 
dissected, transferred to 10% neutral buffered formalin (Fisher Scientific, Hampton, 
NH), and embedded into paraffin blocks. Five micrometer thick formalin-fixed and 
paraffin-embedded biopsy sections were used for histological diagnosis, the expression 
of HERV-K, and other assays. 
43 
 
      This study was carried out in strict accordance with the recommendations in the Guide 
for the Care and Use of Laboratory Animals of the National Institutes of Health. All 
animal facilities of The University of Texas MD Anderson Cancer Center are under the 
direction of full-time veterinarians and are fully accredited by the American Association 
of Accreditation of Laboratory Animal Care. The University of Texas MD Anderson 
Cancer Center complies with the National Institutes of Health’s policy on animal 
welfare, the Animal Welfare Act and all applicable federal, state and local laws.  
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Chapter 4 Results 
4.1 Down-regulation of Kenv expression in multiple human cancer cell lines by 
shRNA knockdown 
      Fluorescence microscopy was used to determine the transfection efficiency in various 
human cancer cell lines transduced with lentiviral particles harboring shRNAenv or 
shRNAc bearing a green fluorescent protein (GFP) reporter.  All cells expressed GFP 
after drug selection (data not shown). The cells were harvested for RNA isolation or 
lysed for immunoblot analysis after at least two weeks post transduction. The expression 
of Kenv mRNA and protein was partially downregulated in cells transduced with 
shRNAenv, compared with expression in cells transduced with shRNAc, as assessed by 
RT-PCR, qRT-PCR, or immunoblot assay using 6H5 mAb (Figures 8-13). A 
significantly reduced expression of HERV-K env RNA was observed in MDA-MB-231 
(p = 0.0004), MDA-MB-435 eB1 (p = 0.0009), SKBR-3 (p = 0.0055), Panc-2 (p = 
0.0318), Panc-1 (p= 0.0221) and A375 (p = 0.0057) cells compared with cells transduced 
with shRNAc, as assessed by qRT-PCR, and this reduction was confirmed in all cell 
lines by RT-PCR. A reduced expression of Kenv protein was also observed by 
immunoblot in all cell lines transduced with shRNAenv, compared with shRNAc 
(Figures 8-13). 
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Figure 8. Down-regulation of Kenv expression in MDA-MB-231 by shRNA 
knockdown. Reduced expression of Kenv mRNA was demonstrated in MDA-MB-231 
cells transduced with Kenv shRNA (shRNAenv) compared with control shRNA 
(shRNAc) (left panel).  The significantly reduced expression of HERV-K env RNA 
determined by qRT-PCR (p = 0.0004) was confirmed by RT-PCR (top right panel). 
Furthermore, the reduced expression of Kenv at the protein level was demonstrated by 
immunoblot assay using 6H5 mAb (bottom right panel). 
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Figure 9. Down-regulation of Kenv expression in MDA-MB-435 eB1 by shRNA 
knockdown. Reduced expression of Kenv mRNA was demonstrated in MDA-MB-435 
eB1 cells transduced with Kenv shRNA (shRNAenv) compared with control shRNA 
(shRNAc) (left panel).  The significantly reduced expression of HERV-K env RNA 
determined by qRT-PCR (p = 0.0009) was confirmed by RT-PCR (top right panel). 
Furthermore, the reduced expression of Kenv at the protein level was demonstrated by 
immunoblot assay using 6H5 mAb (bottom right panel). 
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Figure 10. Down-regulation of Kenv expression in SKBR-3 by shRNA knockdown. 
Reduced expression of Kenv mRNA was demonstrated in SKBR-3 cells transduced with 
Kenv shRNA (shRNAenv) compared with control shRNA (shRNAc) (left panel).  The 
significantly reduced expression of HERV-K env RNA determined by qRT-PCR (p = 
0.0055) was confirmed by RT-PCR (top right panel). Furthermore, the reduced 
expression of Kenv at the protein level was demonstrated by immunoblot assay using 
6H5 mAb (bottom right panel). 
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Figure 13. Down-regulation of Kenv expression in A375 by shRNA knockdown. 
Reduced expression of Kenv mRNA was demonstrated in A375 cells transduced with 
Kenv shRNA (shRNAenv) compared with control shRNA (shRNAc) (left panel).  The 
significantly reduced expression of HERV-K env RNA determined by qRT-PCR (p = 
0.0057) was confirmed by RT-PCR (top right panel). Furthermore, the reduced 
expression of Kenv at the protein level was demonstrated by immunoblot assay using 
6H5 mAb (bottom right panel). 
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4.2 Knockdown of Kenv inhibited cancer cell proliferation and transformation 
      In the cell proliferation assay, all cancer cell lines transduced with shRNAenv had a 
significantly reduced proliferation rate compared to those transduced with shRNAc 
(Figures 14-19A), after 2 to 3 weeks of transduction.  Furthermore, a soft agar assay 
showed significantly reduced colony formation in shRNAenv transduced cells compared 
with shRNAc transduced cells (Figures 14-19 B&C). 
4.3 Knockdown of Kenv inhibited migration of some cancer cell lines in vitro 
      To investigate the influence of Kenv knockdown on migration rate of the cancer cell 
lines in vitro, a time-lapse wound-healing assay was carried out. With transduction of 
shRNAenv, MDA-MB-231, MDA-MB-435 eB1 and A375 cells showed slower wound-
healing rate than the control cells, indicating that the in vitro migration rate of the three 
cell lines was inhibited by knockdown of Kenv (Figures 20, 21&25). However, the 
wound-healing rate of SKBR-3, Panc-2 and Panc-1 transduced with shRNAenv did not 
show apparent differences from that of the control cells, indicating that their in vitro 
migration rate was not influenced by knockdown of Kenv (Figures 22-24). 
      A transwell plate assay was also used to assess the influence of Kenv knockdown on 
migration rate, as well as invasion rate, of MDA-MB-231, SKBR-3 and A375 in vitro. In 
the migration assay plate, a smaller number of shRNAenv transduced MDA-MB-231, 
SKBR-3 and A375 cells than of control cells were observed in the bottom chamber, 
again indicating that the in vitro migration rate was inhibited by knockdown of Kenv.  In 
addition, an invasion plate assay showed that a smaller number of shRNAenv transduced 
MDA-MB-231 and A375 cells than control cells were found under the bottom chamber, 
indicating a slower invasion rate result from knockdown of Kenv (Figure 26).
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Figure 14. Inhibition of cell proliferation and colony formation of MDA-MB-231 cells 
by shRNAenv. A. MDA-MB-231 cells transduced with shRNAenv have a significantly 
decreased proliferation rate than those transduced with shRNAc; B. In the anchorage-
independent colony formation assay, the colony-formation potential of MDA-MB-231 
was significantly inhibited by shRNAenv (p = 0.0034); C. Representative pictures of 
colonies formed from MDA-MB-231 cells transduced with shRNAc or shRNAenv.
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Figure 15. Inhibition of cell proliferation and colony formation of MDA-MB-435 eB1 
cells by shRNAenv. A. MDA-MB-435 eB1 cells transduced with shRNAenv have a 
significantly decreased proliferation rate than those transduced with shRNAc; B. In the 
anchorage-independent colony formation assay, the colony-formation potential of MDA-
MB-435 eB1 was significantly inhibited by shRNAenv (p = 0.0046); C. Representative 
pictures of colonies formed from MDA-MB-435 eB1 cells transduced with shRNAc or 
shRNAenv.
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Figure 16. Inhibition of cell proliferation and colony formation of SKBR-3 cells by 
shRNAenv. A. SKBR-3 cells transduced with shRNAenv have a significantly decreased 
proliferation rate than those transduced with shRNAc; B. In the anchorage-independent 
colony formation assay, the colony-formation potential of SKBR-3 was significantly 
inhibited by shRNAenv (p = 0.0039); C. Representative pictures of colonies formed from 
SKBR-3 cells transduced with shRNAc or shRNAenv. 
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Figure 17. Inhibition of cell proliferation and colony formation of Panc-2 cells by 
shRNAenv. A. Panc-2 cells transduced with shRNAenv have a significantly decreased 
proliferation rate than those transduced with shRNAc; B. In the anchorage-independent 
colony formation assay, the colony-formation potential of Panc-2 was significantly 
inhibited by shRNAenv (p = 0.0104); C. Representative pictures of colonies formed from 
Panc-2 cells transduced with shRNAc or shRNAenv.
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Figure 18. Inhibition of cell proliferation and colony formation of Panc-1 cells by 
shRNAenv. A. Panc-1 cells transduced with shRNAenv have a significantly decreased 
proliferation rate than those transduced with shRNAc; B. In the anchorage-independent 
colony formation assay, the colony-formation potential of Panc-1 was significantly 
inhibited by shRNAenv (p = 0.0073); C. Representative pictures of colonies formed from 
Panc-1 cells transduced with shRNAc or shRNAenv.
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Figure 19. Inhibition of cell proliferation and colony formation of A375 cells by 
shRNAenv. A. A375 cells transduced with shRNAenv have a significantly decreased 
proliferation rate than those transduced with shRNAc; B. In the anchorage-independent 
colony formation assay, the colony-formation potential of A375 was significantly 
inhibited by shRNAenv (p = 0.0016); C. Representative pictures of colonies formed from 
A375 cells transduced with shRNAc or shRNAenv. 
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Figure 20. Time-lapse wound-healing assay of shRNA transduced MDA-MB-231 cells. 
The wound of shRNAenv transduced  MDA-MB-231 cells healed slower, indicating a 
decreased migration rate in vitro.
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Figure 21. Time-lapse wound-healing assay of shRNA transduced MDA-MB-435 eB1 
cells. The wound of shRNAenv transduced  MDA-MB-435 eB1 cells healed slower, 
indicating a decreased migration rate in vitro.
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Figure 22. Time-lapse wound-healing assay of shRNA transduced SKBR-3 cells. The 
wound-healing rate of the two shRNA transduced SKBR-3 cells did not exhibit an 
apparent difference, indicating a similar migration rate in vitro.
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Figure 23. Time-lapse wound-healing assay of shRNA transduced Panc-2 cells. The 
wound-healing rate of the two shRNA transduced Panc-2 cells did not exhibit an 
apparent difference, indicating a similar migration rate in vitro. 
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Figure 24. Time-lapse wound-healing assay of shRNA transduced Panc-1 cells. The 
wound-healing rate of the two shRNA transduced Panc-1 cells did not exhibit an 
apparent difference, indicating a similar migration rate in vitro.
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Figure 25. Time-lapse wound-healing assay of shRNA transduced A375 cells. The 
wound of shRNAenv transduced  A375 cells healed slower, indicating a decreased 
migration rate in vitro. 
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4.4 Knockdown of Kenv reduced tumor growth in xenograft models 
      To investigate the potential effect of Kenv on the growth of cancer cell lines in vivo, 
SKBR-3, Panc-2 or Panc-1 cells transduced with shRNAenv or shRNAc were 
subcutaneously injected  into nude mice to generate human tumor xenografts. Reduced 
growth of tumor xenografts were observed when the cells were transduced with 
shRNAenv, and in particular, the reduction is significant (p = 0.0074) with regard to 
Panc-1 cells (Figures 27-29). It is noteworthy that not every injection resulted an 
xenograft tumor (eg.  7 out of 10 injections of shRNAenv tranduced Panc-2 resulted in 
xenograft tumor growth, while 5 out of 10 injections of shRNAc tranduced Panc-2 
resulted in xenograft tumor growth) , and the tumor size varied a lot even in the same 
experimental group. 
      Further, MDA-MB-231, MDA-MB-435 eB1, SKBR-3, Panc-2 or A375 cells 
transduced with shRNAenv or shRNAc were subcutaneously injected  into NSG mice to 
generate human tumor xenografts. Growth curves of these xenografts over 3-8 weeks 
showed that the shRNAenv transduced groups displayed a significantly lower growth 
rate compared to control groups (Figures 30-34 A). Tumor sizes and weights were 
significantly reduced in NSG mice harboring cancer cells transduced with shRNAenv 
compared with control mice (Figures 30-34 B). H&E staining showed no significant 
changes in histology of tumor biopsies from either groups, except that the control tumors 
appeared to have more tumor necrosis, possibly due to a less blood supply to tumor mass 
ratio (an example was shown in Figure 35).  
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Figure 27. Inhibition of growth of SKBR-3 xenograft tumors in nude mice by 
shRNAenv transduction. Smaller tumor sizes (left panel) and reduced tumor weights 
(right panel) were observed when SKBR-3 cells transduced with shRNAenv were grown 
as xenografts, compared with control cells. 
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Figure 28. Inhibition of growth of Panc-2 xenograft tumors in nude mice by shRNAenv 
transduction. 5 out of 10 injections of shRNAenv tranduced Panc-2 resulted in xenograft 
tumor growth, while 7 out of 10 injections of shRNAc tranduced Panc-2 resulted in 
xenograft tumor growth.  Smaller tumor sizes (left panel) and reduced tumor weights 
(right panel) were observed when Panc-2 cells transduced with shRNAenv were grown 
as xenografts, compared with control cells. 
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Figure 29. Inhibition of growth of Panc-1 xenograft tumors in nude mice by shRNAenv 
transduction. 9 out of 10 injections of shRNAenv tranduced Panc-1 resulted in xenograft 
tumor growth, while 7 out of 10 injections of shRNAc tranduced Panc-1 resulted in 
xenograft tumor growth.  Smaller tumor sizes (lower panel) and significantly reduced 
tumor weights (p = 0.0074, upper panel) were observed when Panc-2 cells transduced 
with shRNAenv were grown as xenografts, compared with control cells. 
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      Down-regulation of Kenv mRNA expression in the tumor biopsies of MDA-MB-231, 
MDA-MB-435 eB1, Panc-2 and A375 was further confirmed by RT-PCR and qRT-PCR, 
respectively (Figures 36-39), and down-regulation of Kenv protein expression in the 
A375 tumor biopsies was also confirmed by immunoblot (Figure 39). 
      Of interest, GFP+ Panc-2 cells were observed in dissociated and cultured lung tissues 
collected from control shRNAc mice, but were strikingly absent in lung tissues of 
shRNAenv mice (Figure 40). The same observation can be found in the sections of the 
lung tissues (Figure 41). Similar results was observed in the case of shRNA transduced 
MDA-MB-231, but the GFP+ MDA-MB-231 cell numbers were fewer, instead of absent, 
in the lung tissues of shRNAenv mice (Figure 42&43). This finding suggests a role for 
Kenv in enabling the formation of distant metastases. 
4.5 Differential gene expression profiling by RNA-Seq and IPA 
      We performed whole genome RNA-Seq analysis of xenografts from transduced 
SKBR-3, Panc-2, Panc-1 and A375, as well as of the transduced MDA-MB-435 
eB1cells. The results were subjected to IPA analysis to identify the Kenv-related 
networks of differentially expressed genes in our samples. A brief summary for each pair 
of shRNAenv/shRNAc xenografts or cells is shown in Tables 4-9, and an overall 
summary across all samples is shown in Table 10. In common, Cancer, Gastrointestinal 
Disease and Dermatological Diseases and Conditions are the top three diseases and 
disorders related to Kenv; Kenv is highly related to several molecular and cellular 
functions: Cellular Growth and Proliferation, Cellular Movement, Cell Death and 
Survival, Cellular Development.  The top canonical pathway in common is Hepatic 
Fibrosis / Hepatic Stellate Cell Activation (Table 10). 
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Figure 36. Down-regulation of Kenv mRNA expression in MDA-MB-231 xenograft 
tumor biopsies. Kenv mRNA expression was significantly decreased in the tumor 
biopsies of shRNAenv transduced cells compared with the control cells, as assessed by 
qRT-PCR (p = 0.0449). 
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Figure 37. Down-regulation of Kenv mRNA expression in MDA-MB-435 eB1 
xenograft tumor biopsies. Kenv mRNA expression was significantly decreased in the 
tumor biopsies of shRNAenv transduced cells compared with the control cells, as 
assessed by qRT-PCR (p = 0.0006). 
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Figure 40. GFP+ Panc-2 cells in cultured lung tissue of NSG mice bearing xenograft 
tumors. Expression of GFP was observed in three lung biopsies of mice bearing 
xenografts of Panc-2 cells transduced with shRNAc (left panel) but not in those with 
shRNAenv (right panel). 
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Figure 41. GFP+ Panc-2 cells in sections of lung tissue from NSG mice bearing 
xenograft tumors. Expression of GFP was observed in sections of lung biopsies from 
mice bearing xenografts of Panc-2 cells transduced with shRNA, but not in those with 
shRNAenv. 
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Figure 42. GFP+ MDA-MB231 cells in cultured lung tissue of NSG mice bearing 
xenograft tumors. More GFP+ cells were observed in three lung biopsies of mice bearing 
xenografts of MDA-MB-231 cells transduced with shRNAc than in those with 
shRNAenv, both in the floating pieces of lung tissues (upper panel) and among the 
attached cells (lower panel) 
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Figure 43. GFP+ MDA-MB-231 cells in sections of lung tissue from NSG mice bearing 
xenograft tumor. More GFP+ cells were observed in sections of lung biopsies from mice 
bearing xenografts of MDA-MB-231 cells transduced with shRNAc than those with 
shRNAenv. 
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Table 4. A brief summary of IPA results of shRNA transduced MDA-MB-435 eB1 cells. 
Some top Bio-functions and top canonical pathways that are related to Kenv are shown 
in the table. 
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Table 5. A brief summary of IPA results of SKBR-3 xenografts growing in NSG mice. 
Some top Bio-functions and top canonical pathways that are related to Kenv are shown 
in the table. 
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Table 6. A brief summary of IPA results of SKBR-3 xenografts growing in nude mice. 
Some top Bio-functions and top canonical pathways that are related to Kenv are shown 
in the table. 
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Table 7. A brief summary of IPA results of Panc-2 xenografts growing in nude mice. 
Some top Bio-functions and top canonical pathways that are related to Kenv are shown 
in the table. 
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Table 8. A brief summary of IPA results of Panc-1 xenografts growing in nude mice. 
Some top Bio-functions and top canonical pathways that are related to Kenv are shown 
in the table. 
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Table 9. A brief summary of IPA results of A375 xenografts growing in NSG mice. 
Some top Bio-functions and top canonical pathways that are related to Kenv are shown 
in the table. 
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Cells or xenografts Panc-1 Panc-2 SKBR-3 
(nude) 
SKBR-3 
(NSG) 
eB1 A375 
Diseases and Disorders       
    Cancer √ √ √ √ √ √ 
    Gastrointestinal Disease √ √ √ √ √ √ 
    Dermatological Diseases and Conditions √ √ √ √  √ 
    Organismal Injury and Abnormalities √  √ √   
Molecular and Cellular Functions       
    Cellular Growth and Proliferation √ √ √ √ √ √ 
    Cellular Movement √ √ √ √ √ √ 
    Cell Death and Survival  √ √ √ √ √ 
    Cellular Development  √ √ √ √ √ 
    Cell Morphology √   √ √  
Top Canonical Pathways       
    Hepatic Fibrosis / Hepatic Stellate Cell       
Activation  
√ √ √   √ 
    Axonal Guidance Signaling √ √    √ 
 
Table 10. An overall summary of IPA results across all samples. Only Bio-functions or 
pathways that are common in more than three samples are listed above.  
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      Of great interest, we found changes in expression of several genes involved in the 
mevalonate pathway, which is very similar to the important findings published by Freed-
Pastor et al. (84), as shown in Figure 44. We then validated our RNA Seq results by 
subjecting these genes by qRT-PCR assays (two step). The results showed that all the 
genes were downregulated with knockdown of Kenv, and this again matches the results 
reported by Freed-Pastor et al. (Figure 45). 
4.6 Over-expression of Kenv promoted MCF-10AT cell proliferation and 
transformation in vitro 
      To investigate the roles of Kenv in human cancer in another way, gain-of-fuction 
approach was used with over-expression of Kenv in the premalignant human breast cell 
line MCF-10AT. The Kenv-expressing lentivector pLVX-Kenv was transduced into 
MCF10AT, and the empty vector pLVX was used as control. MCF-10AT cells had an 
increased Kenv mRNA expression, and an emerging Kenv protein expression with 
transduction of pLVX-Kenv (Figure 46).  With over-expression of Kenv, the 
proliferation rate of MCF-10AT cells were significantly increased (Figure 47A). In 
addition, a soft agar assay showed significantly increased colony formation in pLVX-
Kenv transduced cells compared with the control cells (Figure 47B&C). However, when 
subcutaneously inoculated into NSG mice, MCF-10AT cells transduced with pLVX-
Kenv didn’t develop any xenograft tumors after two months post inoculation (data not 
shown).
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Figure 45. Validation of genes involved in the mevalonate pathway by qRT-PCR. 8 
genes involved in the mevalonate pathway as well as Kenv, were tested by qRT-PCR, 
with normalization to RPL32. All genes were down-regulated accompanying by 
knockdown of Kenv, and the levels of HMGCR and DHCR24 were significantly 
decreased. 
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Figure 46. Over-expression of Kenv expression in MCF-10AT by lentivector 
transduction. Increased expression of Kenv mRNA was demonstrated in MCF-10AT 
cells transduced with pLVX-Kenv compared with pLVX (left panel).  The significantly 
increased expression of HERV-K env RNA determined by qRT-PCR (p = 0.0002) was 
confirmed by RT-PCR (top right panel). Furthermore, the increased expression of Kenv 
at the protein level was demonstrated by immunoblot assay using 6H5 mAb (bottom 
right panel). 
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Figure 47. Promotion of cell proliferation and colony formation of MCF-10AT cells by 
pLVX-Kenv. A. MCF-10AT cells transduced with pLVX-Kenv have a significantly 
increased proliferation rate than those transduced with pLVX; B. In the anchorage-
independent colony formation assay, the colony-formation potential of MCF-10AT was 
significantly increased by pLVX-Kenv (p < 0.0001); C. Representative pictures of 
colonies formed from MCF-10AT cell transduced with pLVX-Kenv or pLVX. 
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Chapter 5 Discussion 
      In the US, it is estimated that more than 1.6 million new cancer cases will be 
diagnosed and more than half a million cancer patients will die in 2013 (54). The high 
incidence, high mortality and high cost for treatment of cancer have made it one of the 
most serious health issues in the US.  
      There are many risk factors for cancer development, and among them, viruses are 
considered as the second most important one in humans, only exceeded by tobacco 
consumption (90). Recently, many publications have been illustrating the association 
between HERV-K and cancer. However, as mentioned in Chapter 1, the causal 
relationship between the two is still unknown. But some studies (41, 75, 77) have 
suggested that HERV-K might play the causal role. Of our great interest, Kenv protein 
seems to play an important role in this process, though its actual role remains a mystery. 
In this project, we tried to figure out the role(s) of Kenv in carcinogenesis or tumor 
progression of human breast cancer, pancreatic cancer and melanoma, whose association 
with HERV-K has been intensively investigated in our lab in recent years. We used two 
different approaches: knockdown of Kenv in cancer cell lines, to see if down-regulation 
of Kenv could make these cancer cell lines become less tumorigenic; over-expression of 
Kenv in normal or premalignant cell lines, to see if up-regulation of Kenv could 
transform these cell lines. 
      To study the role of Kenv using the knockdown approach, we first tried short 
interfering RNAs (siRNAs). Six individual siRNAs (25-mer) were designed to target 
HERV-K env using the Invitrogen Block-iT RNAi Designer and transiently transfected 
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into different cancer cell lines to test their knockdown efficacies. Though the knockdown 
of Kenv at the mRNA level was observed, reduction of Kenv protein was not observed 
with siRNA transfection (data not shown). One reason behind this observation might be 
the long half-life of Kenv protein: when we carried out an 35S pulse-chase experiment to 
study the half-life of Kenv protein, we did not see an obvious decrease in the level of 
35S-labeled Kenv protein even after 7 days post 35S. The Kenv protein could be so stable 
that the siRNAs transiently transfected into the cells might have already been degraded 
before the level of Kenv protein went down, though the Kenv mRNA had been knocked 
down by these siRNAs. In addition, to investigate the knockdown effect of Kenv in vivo, 
stably knocking down of Kenv expression is required, so we decided to use shRNA 
approach instead. 
            Oricchio et al. reported a retroviral vector-based shRNA that could knockdown 
HERV-K expression (pS-H-Ki), though it targets HERV-K gag (74). We tried the same 
shRNA vector in our lab. With transduction of pS-H-Ki, we did observe the decreased 
expression of HERV-K genes and Kenv protein as well as smaller tumor formation in 
mice compared to the parent A375 cells. This result is in agreement with Oricchio et al.. 
However, the transduction of the scrambled control shRNA, or even of the vector control 
only (without any shRNA insert), could also lead to the decreased HERV-K expression 
and smaller tumor formation in mice compared to the parent cells though there was no 
significant difference between the pS-H-Ki transduced  cells and the control shRNA 
transduced cells. This perhaps resulted from the variance of the single colonies picked up 
(following the manufacturer’s manual) or from the long-term drug selection. In addition, 
the HERV-K gene we are interested in is env, not gag. So we decided to design our own 
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HERV-K-specific shRNA targeting env and to express it in targeting cells using a 
lentivector system which has higher transduction efficiency than retroviral vectors . 
      Kenv-targeting shRNA sequences (19-mer) were designed with the help of the 
Invitrogen Block-iT RNAi Designer, and compared to the siRNA sequence (25-mer) 
with the best knockdown efficacy among the 6 siRNAs, which was determined by the 
previous study. One shRNA sequence that overlaps the majority of the best siRNA 
sequence was chosen, and cloned into the pGreenPuro™ lentivector. Because of the high 
transduction efficiency of lentivector systems, more than 90% of cells were transduced 
as determined by levels of expressed GFP reporter signals. Then the pool of transduced 
cells after drug selection, rather than single colonies randomly picked up, were used in 
all the assays to minimize the influence of varieties of single colonies.   
     Our data showed that Kenv expression at both mRNA level and protein level was 
successfully knocked down by shRNAenv in all the 6 cell lines we tried (MDA-MB-231, 
MDA-MB-435 eB1, SKBR-3, Panc-2, Panc-1 and A375), no matter which cancer types 
they belong to (Figures 8-13). Perhaps because of the high variety and complexity of 
HERV-K family, shRNAenv didn’t completely, or even nearly, knock out its targeting 
gene/protein like other shRNAs reported previously did. However, the in vitro 
proliferation and colony formation of all 6 cell lines were significantly decreased 
accompanied by knockdown of Kenv (Figures 14-19), and the in vitro migration/ 
invasion of MDA-MB-231, MDA-MB-435 eB1 and A375 was also decreased (Figures 
20-26). In addition, tumor growth in mice in the xenograft models of all the cell lines 
were also inhibited by shRNAenv (Figures 27-34) and the in vivo migration of MDA-
MB-231 and Panc-2 was inhibited by shRNAenv (Figures 40-43). These results strongly 
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suggest that Kenv plays a very important role in tumor progression in breast cancer, 
pancreatic cancer, and melanoma.  
      The studies reported by Oricchio et al. (74) and Serafino et al. (75) seemed to 
demonstrate the importance of HERV-K Gag protein in melanoma progression as well. 
However, when shRNAenv was used to transduce A375 cells, the expression of other 
HERV-K genes including gag were decreased; meanwhile, when shRNA targeting 
HERV-K gag was used, the expression of other HERV-K genes including env were also 
decreased (Figure 48). This could be explained by the RT-PCR results using primers P1 
and P3, which is intended to amplify a HERV-K gene fragment that spans the pol and 
env regions; the  amplicons showed the possible existence of a mRNA with all HERV-K 
genes, or HERV-K genomic RNA in A375 cells, and shRNA targeting any single 
HERV-K gene may result in knockdown of all the HERV-K genes. So the efficacy of 
shRNA targeting HERV-K gag might eventually rely on the knockdown of Kenv, and 
combined with our studies in breast cancer with anti-Kenv antibodies (30), we think 
Kenv is the very HERV-K protein that influences melanoma progression. However, this 
should be further demonstrated by the rescue assay, which we are focusing on right now. 
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Figure 48. “Cross-reaction” ability of shRNAs targeting different HERV-K genes. 
Multiple shRNAs were used to transduce A375 cells, and all HERV-K genes may be 
knocked down by shRNA targeting any HERV-K gene, measured by RT-PCR. 
β-actin 
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gag 
Ty1 env 
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      To understand the mechanism of how Kenv influences the tumorigenic 
characteristics of the cancer cell lines, we performed whole genome RNA-Seq analysis 
of xenografts from the shRNA transduced SKBR-3, Panc-2, Panc-1 and A375, as well as 
of the shRNA transduced MDA-MB-435 eB1 cells, trying to find out the differential 
gene expression profiling related to knockdown of Kenv. Then IPA was done to identify 
the Kenv-related networks of differentially expressed genes in our samples. In summary, 
our results show that Kenv is highly related to cellular growth and proliferation, cellular 
movement and cell death and survival, which suggests that to understand how Kenv 
works, a close attention need be paid to genes/pathways related to these cellular and 
molecular functions. 
      In particular, we noticed that some genes involved in the mevalonate pathway had a 
differential expression in shRNA transduced MDA-MB-435 eB1 cells, and a similar 
finding was observed in the important study published by Freed-Pastor et al. (84), as 
shown in Figure 44. Thus we performed qRT-PCR following Freed-Pastor et al., 
primarily to validate our RNA Seq results, and the results showed that expression levels 
of some genes that are involved in the mevalonate pathway were indeed down-regulated 
with knockdown of Kenv (Figure 45). Freed-Pastor’s study demonstrated that the 
mevalonate pathway is related to mutant p53 and we also reported that Kenv is related to 
p53 pathways (30), so we infer that the Kenv influence cancer development by changing 
mevalonate pathways especially in breast cancer, which is intermediated by mutant p53, 
given that MDA-MB-435 eB1 is a p53 mutant cell line (though it has different mutations 
of p53 than MDA-MB231/ MDA-MB-468 that were used by Freed-Pastor et al.) (91). 
However, much further work need to be done to support this notion. 
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      In addition, the study with over-expression of Kenv approach has just been started. 
At the beginning, we expected to find that over-expression of Kenv in the premalignant 
human breast cell line MCF-10AT could transform this cell line, like the role of Bmi-1 
reported by Datta et al. (92). However, after successfully introducing Kenv into MCF-
10AT, while we did observe an increased proliferation rate and more colonies formation 
in the soft agar assay as expected, we did not find any tumor formation that was resulted 
from inoculation of pLVX-Kenv transduced MCF-10AT. This might be because Kenv is 
not as oncogenic as Bmi-1, or other co-factors may be also needed to initiate the 
malignant transformation. Another possibility is that Kenv could act as a promotor, 
rather than initiator, in tumor development. Further studies should be carried out in some 
human cancer cell lines (such as human breast cancer cell lines MCF-7 and SKBR-3) to 
determine if Kenv over-expression could increase the malignancy of these cancer cell 
lines.   
      This study has a few limitations. First, the studies of melanoma focused on only one 
cell line, so the results might not be representative, and thus similar studies should be 
carried out with additional melanoma cell lines. Second, the specificity of the shRNAenv 
has not been definitively demonstrated, and this should be further addressed by a rescue 
assay, which is currently being carried out in our lab. Third, although some possible 
pathways through which Kenv might influence human cancer progression have been 
proposed by IPA, these pathways have not been validated yet, and the position of Kenv 
in these pathways has still not been determined. Additional studies are needed to 
illustrate the detail of the pathways. Moreover, the role of Kenv in multiple human 
cancers should be further demonstrated with overexpression approaches. 
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      In summary, our data suggest that Kenv protein could positively influence the 
proliferation, migration, invasion, and tumorigenic potential of multiple cancer cell lines, 
but it appears that Kenv may not initiate tumor development in vivo. To our knowledge, 
this is the first study to illustrate the role of Kenv protein in human breast cancer, 
pancreatic cancer, and melanoma. Importantly, here we have briefly described the 
pathways in which Kenv protein might be involved in cancer development, paving a way 
to study the detailed mechanism of how Kenv protein works in the cells. These results 
suggest that Kenv plays specific and important roles in progression of  human breast 
cancer, pancreatic cancer and melanoma. 
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